NOV-002, a mimetic of glutathione disulfide.
BACKGROUND
Oxidative signaling to modulate redox-sensitive cell functions is a heretofore unexploited approach to developing new drugs for poorly treated oncology indications, where current therapies are often only palliative and accompanied by severe toxicities.


OBJECTIVE
Clinical and non-clinical findings with NOV-002 (a mimetic of glutathione disulfide that represents such an approach) are reviewed and evaluated.


METHODS
Published data on NOV-002 along with unpublished information from the drug's sponsor were reviewed. Literature analysis also focused on protein S-glutathionylation as a regulatory mechanism, particularly in relation to cell signaling, proliferation and cytoskeletal architecture.


CONCLUSIONS
NOV-002 is a mechanistically novel agent with potential for ameliorating hematologic toxicity and enhancing efficacy when used in combination with standard chemotherapy to treat cancer patients.
Medical University of South Carolina, Department of Pharmaceutical Sciences, 173 Ashley Avenue, PO Box 250505, Charleston, SC 29425, USA.
Danyelle M
DM
Townsend
Christopher J
CJ
Pazoles
Kenneth D
KD
Tew
D000818:Animals; D002945:Cisplatin / Q000009:adverse effects / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D004338:Drug Combinations; D004361:Drug Tolerance; D019803:Glutathione Disulfide / Q000009:adverse effects / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D018716:Molecular Mimicry; D015394:Molecular Structure
D004338:Drug Combinations; C529375:NOV 002; D002945:Cisplatin; D019803:Glutathione Disulfide